A prospective clinical utility study demonstrates that physicians use the 40-gene expression profile (40-GEP) to guide clinical management decisions for Medicare-eligible patients with cutaneous squamous cell carcinoma (cSCC). J of Skin [Internet]. 2022 Nov. 16 [cited 2025 Apr. 19];6(6):s95. Available from: https://skin.dermsquared.com/skin/article/view/1854